Small case study of ivermectin + doxycycline with 8 cancer patients, with all patients becoming PCR- by day 6 when tested again.
Hussain et al., 11 Dec 2020, preprint, 3 authors.
Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh
Syed Md Akram Hussain, Md Shuayb, Mahmudur Rahman
International Journal of Molecular & Immuno Oncology, doi:10.25259/ijmio_30_2020
is is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
References
Caly, Druce, Catton, Jans, Wagstaff, e FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Cortiula, Pettke, Bartoletti, Puglisi, Helleday, Managing COVID-19 in the oncology clinic and avoiding the distraction effect, Ann Oncol
Hussain, Shuayb, Rahman, Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh, Int J Mol Immuno Oncol,
doi:10.25259/IJMIO_30_2020
Hussman, Cellular and Molecular Pathways of COVID-19 and Potential Points of erapeutic Intervention, Front Pharmacol
Maurya, A Combination of Ivermectin and Doxycycline Possibly Blocks the Viral Entry and Modulate the Innate Immune Response in COVID-19 Patients